Fas ligand-transfected myoblasts and islet cell transplantation

Transplantation

Volumn 69, Issue 9, 2000, Pages 1972-1976

  Turvey, Stuart E ^a   Gonzalez Nicolini, Valeria ^b   Kingsley, Cherry I ^a   Larregina, Adriana T ^b,c   Morris, Peter J ^a   Castro, Maria G ^b   Lowenstein, Pedro R ^b   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ALLOGRAFT; ANIMAL CELL; APOPTOSIS; ARTICLE; COMPOSITE GRAFT; GENETIC TRANSFECTION; IMMUNE RESPONSE; LIGAND BINDING; MOUSE; MYOBLAST; NONHUMAN; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 0034658457     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005150-00043     Document Type: Article

References (12)

1. Lau HT, Yu M, Fontana A, Stoeckert CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
2. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
3. Kang S-M, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738.
4. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997; 94: 13862.
5. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3: 165.
6. Chen J, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714.
7. Kang S, Hofmann A, Le D, Springer ML, Stock PG, Blau HM. Immune response and myoblasts that express Fas ligand. Science 1997; 278: 1322.
8. Wernig A, Irintchev A, Hartling A, Stephan G, Zimmermann K, Starziniski-Powitz A. Formation of new muscle fibres and tumours after injection of cultured myogenic cells. J Neurocytol 1991; 20: 982.
9. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275.
10. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J Immunol 1995; 155: 4147.
11. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287.
12. Seino K, Iwabuchi K, Kayagaki N, et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161: 4484.